Symbols

RDY

Dr. Reddy'S Laboratories

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 4

Sell signal 2

Consensus Rating "Strong Buy"

Bearish Engulfing

Ample Liquidity

High Gross Profit Margin

EPS Beats Expectation

Bearish Abandoned Baby

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RDY

Dr. Reddy'S Laboratories Limited

An Indian developer of active pharmaceutical ingredients, intermediates, and finished dosage forms

Industry

Pharmaceutical

Established Date

02/24/1984

Listing Date

04/11/2001

Exchange

New York Stock Exchange

Full-time Employees

27,811

Fiscal Year Ends

03-31

Website

www.drreddys.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India

Business

Introduction

Dr. Reddy'S Laboratories Limited, established on February 24, 1984, is an integrated global pharmaceutical company dedicated to providing new drugs at affordable prices through its three core business divisions: Global Generics Division, Pharmaceutical Services and Active Ingredients Division (PSAI) and Proprietary Products Division. Its global branded and unbranded generic drug segment includes prescription and over-the-counter (OTC) drug operations. The company's Pharmaceutical Services and Active Ingredients Division (PSAI) consists of the Pharmaceutical Ingredients (API) business and customized pharmaceutical services. The company's patented product section consists of biopharmaceutical companies, new chemical entity business, differentiated formulation business and dermatological professional business key enterprises operated by promius pharmaceutical company.

Company Financials

EPS

RDY has released its 2025 Q4 earnings. EPS was reported at 0.22, versus the expected 0.1859523258457, beating expectations. The chart below visualizes how RDY has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

RDY has released its 2025 Q4 earnings report, with revenue of 995.67M, reflecting a YoY change of 17.15%, and net profit of 185.80M, showing a YoY change of 18.47%. The Sankey diagram below clearly presents RDY's revenue sources and cost distribution.